Associated tags: SCI, Robotics, Stroke, Quality of life, ReWalk, Habitat for Humanity, Rehabilitation, Medicare
Locations: UNITED STATES, MIAMI, FL, HUNGARY, MARLBORO, MA, US, ISRAEL, GERMANY
Key Points:
- MARLBOROUGH, Mass.
- and YOKNEAM ILLIT, Israel, May 07, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, today announced that the Company will release its first quarter 2024 financial results before the markets open on Wednesday, May 15, 2024.
- Larry Jasinski, Chief Executive Officer, and Michael Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EDT to discuss the financial results.
- To access the call, analysts and investors may utilize the following:
CMS,
DBA,
Brain damage,
Muscular dystrophy,
Disability,
General Electric Company,
GE HealthCare,
Robotics,
Amputation,
Face,
ALS,
Rehabilitation,
Tetraplegia,
Multiple sclerosis,
Cerebral palsy Mr. Swinford held various operational and commercial roles throughout his career leading through various business cycles from start-ups to turnarounds.
Key Points:
- Mr. Swinford held various operational and commercial roles throughout his career leading through various business cycles from start-ups to turnarounds.
- “As someone who is passionate about improving healthcare access and inclusion for people with disabilities, I am excited to join the Board of Directors of Lifeward,” said Mr. Swinford.
- This is another step to increase the direct commercialization skills and experience within our Board.
- We are delighted to welcome Mike to the Board.”
CMS,
DBA,
Robotics,
Durable medical equipment,
Patient,
Physician,
Face,
Medicare,
Rehabilitation,
Disability,
Health insurance CMS states that it calculated this final payment amount by averaging pricing information for exoskeleton devices from Lifeward and other manufacturers.
Key Points:
- CMS states that it calculated this final payment amount by averaging pricing information for exoskeleton devices from Lifeward and other manufacturers.
- “This CMS publication finalizes the payment rate for the ReWalk Personal Exoskeleton for 2024, which importantly concludes all open items related to establishing Medicare benefit category assignment, coding, and reimbursement,” said Larry Jasinski, CEO of Lifeward.
- The final payment rate is in effective for Medicare claims with dates of service on or after April 1, 2024.
- To learn more about Medicare reimbursement for Lifeward’s ReWalk Personal Exoskeleton, please visit GoLifeward.com/Medicare.
HCPCS,
Durable medical equipment,
Disability,
Freedom,
Face,
Robotics,
DBA,
Macs,
Medicare,
CMS,
SCI,
Rehabilitation MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, today issued an open letter from Larry Jasinski, Chief Executive Officer, to shareholders discussing the Company’s progress with the Centers for Medicare & Medicaid Services (“CMS”) to establish a payment rate for ReWalk Personal Exoskeletons. The full letter is published below:
Key Points:
- As a result of the deferral, the payment rate is not included in CMS’ April 2024 Durable Medical Equipment, Prosthetics, Orthotics and Supplies (“DMEPOS”) fee schedule of Medicare payment rates that are effective April 1.
- Our active engagement with CMS is ongoing and we work to establish the payment rate as soon as possible.
- Until a payment rate for exoskeletons is added to the DMEPOS schedule, the Medicare Administrative Contractors (“MACs”) still have authority to approve and pay claims on a case-by-case basis with discretion to set the payment rate.
- Lifeward intends to submit an additional 60-75 additional Medicare claims by the end of 2024 to accelerate its momentum in expanding access for qualified Medicare beneficiaries.
House,
SCI/D,
Disability,
Congress,
Face,
House Committee,
Health,
Ranking,
Robotics,
DBA,
ReWalk,
Senate,
Representative,
Legislation,
Rehabilitation 6373, the VA Spinal Trauma Access to New Devices (STAND) Act.
Key Points:
- 6373, the VA Spinal Trauma Access to New Devices (STAND) Act.
- The Senate companion bill was introduced by Chairman of the Senate Veterans' Affairs Committee, Senator Jon Tester (D-MT), and the Ranking Member of that committee, Senator Jerry Moran (R-KS).
- The bill also requires VA to report to Congress on their performance regarding the exams and device placements and holds local and regional VA medical centers accountable for performance against these same metrics.
- The Senate bill comes on the same day that ReWalk device user and U.S. Marine Corps Veteran, Brittany Elliott, testified in a legislative hearing in front of the House Committee on Veterans' Affairs, Subcommittee on Health regarding the STAND Act.
Retrieved on:
Wednesday, March 13, 2024
MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 13, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, today announced that effective with the open of the market on Friday, March 15, 2024, the Company will complete a 1-for-7 reverse split of its ordinary shares.
Key Points:
- The Company’s shareholders also voted to authorize the Company’s Board of Directors to approve conforming amendments to the Company’s Articles of Association to reflect any such reverse share split.
- The Board has now resolved to set the reverse share split at the ratio of 1-for-7 shares, and to amend the Company’s Articles of Association accordingly.
- In particular, the Company expects the reverse split to increase the per share price and bid price of its ordinary shares above the minimum $1.00 per share threshold required by Nasdaq.
- The reverse split will reduce the authorized and outstanding number of the Company’s ordinary shares while increasing the par value of the ordinary shares in reverse proportion to the decrease in the number of authorized shares.
Boston University,
CMS,
DBA,
Effectiveness,
Mechanics,
Stroke,
University,
Disability,
Medicare,
Robotics,
Patient,
Rehabilitation,
Habitat for Humanity,
Publication,
Development,
Research,
Face,
Distance,
Rail transport MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 08, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, today highlighted two recent research publications that demonstrate the effectiveness of the unique propulsion training capabilities of the ReStore Exo-Suit for post-stroke rehabilitation.
Key Points:
- Randomized clinical trial demonstrates significant improvements in walking ability for patients receiving therapy with the ReStore Exo-Suit as compared to a matched control group receiving conventional stroke therapy.
- Additional study demonstrates that the improvements in walking speed and distance following high-intensity gait training with the ReStore Exo-Suit were maintained by individuals post-stroke 4 weeks after the intervention had concluded.
- Combined results highlight the clinical value of the ReStore Exo-Suit and its related breakthrough propulsion-augmenting technologies within the Lifeward product development pipeline.
- The ReStore intervention group demonstrated significant improvements compared to the control group, including a 56% increase in 10-meter walking speed, and a 68% improvement in 6-minute walking distance, and the improved performance was demonstrated to persist at the post-intervention follow up assessment.
ReWalk,
CMS,
DBA,
Macs,
Disability,
Medicare,
HCPCS,
Rehabilitation,
Robotics,
Face,
Health insurance MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 01, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, today announced that in CMS’ February 29th HCPCS decision memorandum the pricing decision for personal exoskeletons is deferred to obtain more information about current exoskeleton pricing. CMS accepted that “between the original 2020 HCPCS application and the present, the previous model [of the ReWalk Exoskeleton] has been discontinued in favor of the current model that incorporates additional, clinically significant functionality,” and the agency is open to gaining more information about pricing of the current exoskeleton model.
Key Points:
- CMS issues these HCPCS decision memorandums twice per year, so it is anticipated that a pricing decision would be made in the next cycle, if not earlier.
- As of February 2024, a total of 35 ReWalk Personal Exoskeleton systems have been delivered to Medicare beneficiaries and will continue to be processed accordingly.
- “We set a goal many years ago to help individuals with spinal cord injury achieve broader access to technologies which enable them to walk again.
- To learn more about the Lifeward mission and product portfolio, please visit GoLifeward.com .
Retrieved on:
Tuesday, February 27, 2024
Earnout,
Acquisition,
Operating cost,
Total,
ReWalk,
CMS,
DBA,
Average cost,
AlterG,
Sale,
Home,
GAAP,
Disability,
Medicare,
Organization,
Rehabilitation,
Habitat for Humanity,
Robotics,
Face,
Video game MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, today announced its financial results for the three months and full year ended December 31, 2023.
Key Points:
- Gross margin was 35.5% during the fourth quarter of 2023, compared to 30.9% in the fourth quarter of 2022.
- Total operating expenses in the fourth quarter of 2023 were $8.6 million, compared to $5.7 million in the fourth quarter of 2022.
- Excluding the impact of AlterG, operating expenses were $5.4 million in the fourth quarter of 2023, compared to $5.7 million in the fourth quarter of 2023, down $0.3 million, or -4%.
- Operating loss in the fourth quarter of 2023 was $6.1 million, compared to $5.0 million in the fourth quarter of 2022.
Retrieved on:
Tuesday, February 20, 2024
Key Points:
- MARLBOROUGH, Mass.
- and YOKNEAM ILLIT, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face of physical limitation or disability, today announced that the Company will release its fourth quarter and fiscal year-end 2023 financial results before the markets open on Tuesday, February 27, 2024.
- Larry Jasinski, Chief Executive Officer, and Michael Lawless, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the financial results.
- To access the call, analysts and investors may utilize the following:
